Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

98.050
+2.1502.24%
Volume:16.81M
Turnover:1.64B
Market Cap:171.10B
PE:208.62
High:99.350
Open:95.150
Low:94.800
Close:95.900
52wk High:112.700
52wk Low:69.550
Shares:1.75B
HK Float Shares:1.75B
Volume Ratio:1.98
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.470
ROE:7.01%
ROA:2.23%
PB:7.06
PE(LYR):208.62
PS:9.32

Loading ...

Is Innovent Biologics (SEHK:1801) Undervalued After Securing China Rights To Verzenios?

Simply Wall St.
·
Jul 12

Nomura Adjusts Innovent Biologics' Price Target to HK$123.17 From HK$114.64, Keeps at Buy

MT Newswires Live
·
Jul 10

Bank of America Securities Foresees Valuation Re-rating for Chinese Pharma Sector Driven by Active Licensing Deals, Raises Innovent Bio Target to HK$119.2

Stock News
·
Jul 10

Biotech Stocks Surge as New National Essential Drug List Includes Innovative Therapies

Stock News
·
Jul 10

Movement Alert|Innovent Biologics Rises 3.13% in Regular Trading, Zhongtai International Reaffirms Buy Rating with Target Price of HK$134.50

Market Focus
·
Jul 10

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Reuters
·
Jul 08

INNOVENT BIO Issues Approximately 1.88 Million Shares Under Employee Scheme

Stock News
·
Jul 07

INNOVENT BIO Issues 38.87k New Shares in June; Public Float Remains Compliant

Bulletin Express
·
Jul 07

Innovent Biologics Files HKEX Next-day Return, Share Capital Rises by 1,882,334 Shares

Reuters
·
Jul 07

Movement Alert|Innovent Biologics Falls 3.04% in Regular Trading, Trading at HKD 87.9

Market Focus
·
Jul 07

Innovative Drug Sector Maintains Upward Momentum on Favorable Regulatory Developments and Accelerating Internationalization

Stock News
·
Jul 06

Hong Kong Innovative Drug Stocks Jump With HAIXI PHARMA and INNOCARE up 7%; KEYMED up 5%, REMEGEN up 4%

Tiger Newspress
·
Jul 06

Movement Alert|Innovent Biologics Rises 3.19% in Regular Trading, Eli Lilly Partnership and Mazdutide Insurance Review Catalysts Continue

Market Focus
·
Jul 06

Is Innovent Biologics (SEHK:1801) Still Cheap As Verzenios Rights Lift Growth Hopes?

Simply Wall St.
·
Jul 03

Movement Alert|Innovent Biologics Rises 3.57% in Regular Trading, Lilly Partnership and Mazdutide Insurance Review Catalysts Continue

Market Focus
·
Jul 03

Movement Alert|Innovent Biologics Rises 4.27% in Regular Trading, Eli Lilly Commercialization Deal and Mazdutide Insurance Review Progress

Market Focus
·
Jul 02

China's Innovent Biologics Gains Commercialization Rights for Eli Lilly Breast Cancer Drug

Reuters
·
Jun 30

Innovent, Lilly Team up to Commercialize Verzenios in Mainland China

Reuters
·
Jun 30

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

THOMSON REUTERS
·
Jun 30

Innovent Biologics - Lilly to Continue Manufacturing, Supply, and Development of Verzenios

THOMSON REUTERS
·
Jun 30